Brain natriuretic peptide as a potential novel marker of salt-sensitivity in chronic kidney disease patients without cardiac dysfunction

Hayashi, Mutsuharu; Yasuda, Yoshinari; Suzuki, Susumu; Tagaya, Manaka; Ito, Takehiro; Kamada, Tomohito; Yoshinaga, Masataka; Sugishita, Yoshinori; Fujiwara, Wakaya; Yokoi, Hiroatsu; Izawa, Hideo

doi:10.1007/s00380-016-0867-1

Cited by 4 publications

(2 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sasaki found no significant associations between cIMT or the presence of atherosclerotic plaques and NT-proBNP level [ 38 ]. On the other hand, Asian authors found a positive correlation between cIMT and the concentration of this biomarker in adults with CKD [ 10 , 39 , 40 ].…”

Section: Discussionmentioning

confidence: 99%

NT-proBNP as a Potential Marker of Cardiovascular Damage in Children with Chronic Kidney Disease

Skrzypczyk

Okarska‐Napierała

Pietrzak

et al. 2021

JCM

View full text Add to dashboard Cite

Assessing cardiovascular disease (CVD) in children with chronic kidney disease (CKD) is difficult. Great expectations have been associated with biomarkers, including the N-terminal pro-brain natriuretic peptide (NT-proBNP). This study aimed to determine the correlation between NT-proBNP and cardiovascular complications in children with CKD. Serum NT-proBNP, arterial stiffness, common carotid artery intima-media thickness (cIMT), echocardiographic (ECHO) parameters (including tissue Doppler imaging), and biochemical and clinical data were analyzed in 38 pediatric patients with CKD (21 boys, 12.2 ± 4.2 years). Mean NT-proBNP in CKD patients was 1068.1 ± 4630 pg/mL. NT-proBNP above the norm (125 pg/mL) was found in 16 (42.1%) subjects. NT-proBNP correlated with glomerular filtration rate (GFR) (r = −0.423, p = 0.008), and was significantly higher in CKD G5 (glomerular filtration rate grade) patients compared to CKD G2, G3, and G4 children (p = 0.010, p = 0.004, and p = 0.018, respectively). Moreover, NT-proBNP correlated positively with augmentation index (AP/PP: r = 0.451, p = 0.018, P2/P: r = 0.460, p = 0.016), cIMT (r = 0.504, p = 0.020), and E/E’ in ECHO (r = 0.400, p = 0.032). In multivariate analysis, logNT-proBNP was the only significant predictor of cIMT Z-score (beta = 0.402, 95CI (0.082–0.721), p = 0.014) and P2/P1 (beta = 0.130, 95CI (0.082–0.721), p = 0.014). Conclusions: NT-proBNP may serve as a possible marker of thickening of the carotid artery wall in pediatric patients with CKD. The final role of NT-proBNP as a biomarker of arterial damage, left ventricular hypertrophy, or cardiac diastolic dysfunction in CKD children needs confirmation in prospective studies.

show abstract

Section: Discussionmentioning

confidence: 99%

NT-proBNP as a Potential Marker of Cardiovascular Damage in Children with Chronic Kidney Disease

Skrzypczyk

Okarska‐Napierała

Pietrzak

et al. 2021

JCM

View full text Add to dashboard Cite

show abstract

“…Moreover, SRA1 upregulation exhibited a significant potential in diagnosing CHF patients, demonstrating high sensitivity and specificity in differentiating CHF patients from healthy individuals. Abnormal BNP levels, LAD, LVDd, and rLVEF volume are established diagnostic markers of CHF, and these parameters correspond to other pathogenetic factors, including respiratory failure, pneumonia, and chronic kidney dysfunction [ 22 , 23 , 24 , 25 , 26 ]. Additionally, a previous study demonstrated BNP and LVEF could predict the appropriate therapy and hospitalization in HF patients receiving internal cardioverter defibrillator (ICD) and identified a novel protein, soluble growth stimulation expression gene 2 protein (ST2) as a biomarker for the therapeutic efficiency of ICD [ 27 ].…”

Section: Discussionmentioning

confidence: 99%

Diagnostic and Prognostic Value of Plasma lncRNA SRA1 in Chronic Heart Failure

Yu,

Ge,

Cao

et al. 2024

Rev. Cardiovasc. Med.

View full text Add to dashboard Cite

Background: The pathogenesis and development of chronic heart failure (CHF) may involve long non-coding ribonucleic acid (lncRNA) steroid receptor RNA activator 1 (SRA1), a known cardiomyopathy risk factor and regulator of cardiac myofibroblast activation. This study aimed to investigate the application of SRA1 in the early detection and prediction of CHF. Methods: SRA1 plasma expression was determined in CHF patients and healthy individuals/using real time-quantitative polymerase chain reaction (RT-qPCR). The diagnostic and prognostic value of SRA1 was assessed using receiver operating curve (ROC) and Cox regression analyses. Results: Compared with the healthy controls, the patients with CHF had increased brain natriuretic peptide (BNP) levels, left atrial end-systolic diameter (LAD), left ventricular end-diastolic diameter (LVDd), and decreased left ventricular ejection fraction (LVEF). SRA1 was significantly upregulated in CHF patients as well as positively correlated with BNP level, LAD, and LVDd, and negatively correlated with LVEF. SRA1 could sensitively discriminate CHF patients from healthy individuals and was an independent predictor of adverse event-free survival in CHF patients. Conclusions: Upregulated plasma SRA1 can discriminate patients with CHF from healthy individuals and predict adverse outcomes in CHF patients. Thus, SRA1 is a potential molecular indicator for monitoring chronic heart failure development.

show abstract

Fuxin decoction attenuates doxorubicin-induced heart failure in rats via oxidizing suppression and regulating immune responses

Guo

Zhao

et al. 2018

Journal of Traditional Chinese Medicine

View full text Add to dashboard Cite

Brain natriuretic peptide as a potential novel marker of salt-sensitivity in chronic kidney disease patients without cardiac dysfunction

Cited by 4 publications

References 40 publications

NT-proBNP as a Potential Marker of Cardiovascular Damage in Children with Chronic Kidney Disease

NT-proBNP as a Potential Marker of Cardiovascular Damage in Children with Chronic Kidney Disease

Diagnostic and Prognostic Value of Plasma lncRNA SRA1 in Chronic Heart Failure

Fuxin decoction attenuates doxorubicin-induced heart failure in rats via oxidizing suppression and regulating immune responses

Contact Info

Product

Resources

About